Puma Biotechnology (PBYI) Stock Price, Quote & News

Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 424 248 6500

Website: www.pumabiotechnology.com

Address:

10880 Wilshire Boulevard, Suite 2150, Los Angeles, United States

Night_Owl_Biotech Nov. 13 at 4:54 PM

$KURA is the 61st publicly-held commercial-stage oncology focused bio since 1/1/2013. The attached table lists what happened to the share prices of all 61 since the day after their FDA approval date. We will update this table to reflect KURA's share price as of tomorrow's close to be consistent with the other 60. Of the 61: 1. 17 or 28% were acquired at meaningful gains for shareholders. 15 of the 17 were acquired within 2 years of approval 2. 9 or 15% were acquired at meaningful losses for shareholders 3. 3 bankrupt/delisted. Shareholders lost ~99% 4. 32 are still independent today. Only 5 of the 32 trade at a higher share price today than as of the day after disclosing FDA approval. 5. Only 2 of the 61 scored 2 approvals with meaningful TAMS. We exclude $URGN because both drugs use the same API. Remember DCPH GTHX $PBYI YMAB? Good luck to $DAWN The evidence is overwhelming shareholder value is maximized via M&A exit within 2 years of FDA approval. Of course there will be exceptions $XBI

2 · Reply

Jonnyking Nov. 11 at 3:04 PM

$PBYI short seller went crazy yesterday, and realize they got nothing to cover.... As long as Alan is going to keep his 20% shares until a merge deal is reach at either 12 or 18+, short seller market maker can do whatever....

2 · Reply

Jonnyking Nov. 11 at 2:01 AM

$PBYI This should go back to 5 tomorrow, 20% up on Last Friday on okay er, trigger big retail sell off, and panic sell to under 5.. if we trade back to 5, make sure sell some 5 dollars cc expire in December to collect some free premium, this will trade between 4 and 5 for a long while...if this keep going under 4, great to start a new position...let those criminal do their thing... we might see 2.79 again pretty soon.

0 · Reply

Gladwell Nov. 10 at 9:19 PM

$PBYI watching

0 · Reply

Arcides Nov. 10 at 9:16 PM

$PBYI complete demolition...

0 · Reply

tsingyuanTemp Nov. 10 at 5:59 PM

$PBYI This is called JonnyKing effect, hahaha. Each time JonnyKing said AA is selling Puma, Puma dropped the second day.

1 · Reply

biokvint Nov. 10 at 5:53 PM

$PBYI All indications that this company is going to be sold sooner than later.

0 · Reply

Arcides Nov. 10 at 5:52 PM

$PBYI Is not light volume, very high volume, not good..

0 · Reply

Fred_G_Sanford Nov. 10 at 5:46 PM

$PBYI suspicious trading activity. Better send Prince Harry and Paddington Bear to investigate…

0 · Reply

biokvint Nov. 10 at 5:43 PM

$PBYI Bought 2K. Will see what these games are about.

0 · Reply

Puma Biotechnology: Step By Step In Making A Transition

Nov 7, 2025, 5:05 PM EST - 8 days ago

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 1:16 PM EST - 8 days ago

Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 9 days ago

Puma Biotechnology Reports Third Quarter 2025 Financial Results

Oct 23, 2025, 4:10 PM EDT - 23 days ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Sep 2, 2025, 4:07 PM EDT - 2 months ago

Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 8:53 PM EDT - 3 months ago

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Puma Biotechnology Reports Second Quarter Financial Results

Jul 24, 2025, 4:15 PM EDT - 4 months ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

Jun 25, 2025, 11:06 AM EDT - 5 months ago

Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

May 9, 2025, 9:08 AM EDT - 6 months ago

Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Puma Biotechnology Reports First Quarter Financial Results

Apr 30, 2025, 6:00 AM EDT - 7 months ago

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Apr 28, 2025, 3:03 PM EDT - 7 months ago

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Apr 24, 2025, 4:11 PM EDT - 7 months ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Mar 31, 2025, 4:53 AM EDT - 8 months ago

Puma SE: Undervalued With Tailwinds Ahead

Mar 26, 2025, 9:00 AM EDT - 8 months ago

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Mar 21, 2025, 7:46 AM EDT - 8 months ago

PUMA SE: This Is The Right Time To Buy

Mar 5, 2025, 5:30 PM EST - 9 months ago

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Feb 27, 2025, 9:02 PM EST - 9 months ago

Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 9 months ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:15 PM EST - 9 months ago

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Feb 13, 2025, 4:15 PM EST - 9 months ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 9:01 AM EST - 11 months ago

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Dec 16, 2024, 11:36 AM EST - 11 months ago

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Nov 20, 2024, 8:57 AM EST - 1 year ago

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Nov 7, 2024, 11:09 PM EST - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 10:54 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:10 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jun 3, 2024, 2:33 PM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Jun 2, 2024, 10:01 AM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

May 28, 2024, 9:00 AM EDT - 1 year ago

Puma Biotechnology to Join Russell 3000 Index

May 23, 2024, 5:15 PM EDT - 1 year ago

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 2, 2024, 10:11 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript

Apr 18, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Mar 20, 2024, 8:30 AM EDT - 1 year ago

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Feb 29, 2024, 8:39 PM EST - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Feb 15, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 8:30 AM EST - 1 year ago

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Jan 11, 2024, 4:07 PM EST - 2 years ago

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Dec 14, 2023, 1:41 AM EST - 2 years ago

Puma Biotechnology: Profitable, Troubled, But Worth A Good Look

Dec 11, 2023, 8:30 AM EST - 2 years ago

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Nov 2, 2023, 10:21 PM EDT - 2 years ago

Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:14 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Night_Owl_Biotech Nov. 13 at 4:54 PM

2 · Reply

Jonnyking Nov. 11 at 3:04 PM

2 · Reply

Jonnyking Nov. 11 at 2:01 AM

0 · Reply

Gladwell Nov. 10 at 9:19 PM

$PBYI watching

0 · Reply

Arcides Nov. 10 at 9:16 PM

$PBYI complete demolition...

0 · Reply

tsingyuanTemp Nov. 10 at 5:59 PM

$PBYI This is called JonnyKing effect, hahaha. Each time JonnyKing said AA is selling Puma, Puma dropped the second day.

1 · Reply

biokvint Nov. 10 at 5:53 PM

$PBYI All indications that this company is going to be sold sooner than later.

0 · Reply

Arcides Nov. 10 at 5:52 PM

$PBYI Is not light volume, very high volume, not good..

0 · Reply

Fred_G_Sanford Nov. 10 at 5:46 PM

$PBYI suspicious trading activity. Better send Prince Harry and Paddington Bear to investigate…

0 · Reply

biokvint Nov. 10 at 5:43 PM

$PBYI Bought 2K. Will see what these games are about.

0 · Reply

meatpuppets Nov. 10 at 4:29 PM

$PBYI tax selling

0 · Reply

PSDL75 Nov. 10 at 4:23 PM

$PBYI Good ole Jonny - king of the P&D on PBYI lol

3 · Reply

Cinderella74 Nov. 10 at 4:20 PM

$PBYI maybe we have the appeal court decision

0 · Reply

Fred_G_Sanford Nov. 10 at 4:15 PM

$PBYI they pulled the exact same move after earnings last quarter too

0 · Reply

PSDL75 Nov. 10 at 4:05 PM

$PBYI wow - just wow.... I'm you huckleberry for a reversal here

0 · Reply

Arcides Nov. 10 at 4:01 PM

$PBYI is that what you wanna see after a good earnings report? a complete reversal

1 · Reply

gorillasticday Nov. 10 at 4:01 PM

$PBYI damn anybody, wtf happened?

0 · Reply

Cinderella74 Nov. 10 at 3:43 PM

$PBYI bye bye $5

0 · Reply

Cinderella74 Nov. 10 at 3:06 PM

$PBYI i think it was accidental on friday up.

1 · Reply

PLATINUM_TRADES Nov. 10 at 1:50 AM

$PBYI Nice breakout $6.07 next resistance then it's off then mid $6.00's🌶️🌶️🌶️🌶️

0 · Reply

StockScanners Nov. 8 at 4:59 AM

$PBYI keep watch if this holds above 5.50

0 · Reply

SuperGreenToday Nov. 8 at 2:56 AM

$PBYI Share Price: $5.98 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.40 – $1.73 Target Zone: $2.59 – $3.17 Potential Upside: 75% ROI Time to Expiration: 222 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	249.44M
Revenue (ttm)	230.47M
Net Income (ttm)	30.28M
EPS (ttm)	N/A
PE Ratio	6.74
Forward PE	9.69
Profit Margin	13.14%
Debt to Equity Ratio	0.29

Volume	460,900
Avg Vol	565,238
Day's Range	N/A - N/A
Shares Out	50.39M
Stochastic %K	20%
Beta	1.35
Analysts	Hold
Price Target	$3.50